Zifo Clinical Genomics的动态

As we have been telling you these days, our experience at #4YFN24 has been fantastic!??? And we can think of a better way to end this #MWC24 week than sharing with you what for us is the true spirit of innovation applied to improving children's health than with two testimonials from two spinoffs linked to i4KIDS I i4KIDS-EUROPE that have also participated in this congress. ? Ephion Health, a spinoff of Eurecat - Technology Centre and the Barcelona Children's Hospital Sant Joan de Déu, which has developed a solution aimed at measuring the functional capacity of patients affected by Duchenne Syndrome.? ? https://www.ephion.health/ ? Gate2Brain spinoff of the Universitat de Barcelona and Barcelona Children's Hospital Sant Joan de Déu, a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier to treat paediatric brain tumours.? ? https://gate2brain.com/ ? Both are excellent examples of the potential that talent, innovation, research and collaboration have in the field of paediatric, foetal and maternal health and that give true meaning to our mission at #i4KIDS! ?? Thanks to Sebastian Idelsohn Zielonka, CSO of Ephion Health and Meritxell Teixido, CEO of Gate2Brain for sharing your experience at 4YFN and putting into words the need to continue supporting innovation in paediatrics! #Paediatrics #PaediatricInnovation #HealthInnovation

?? Revolutionizing Neonatal Care with Early IV Infiltration Detection?? As a researcher focused on improving neonatal vascular access, I’m excited to see how advancements in technology are helping clinicians detect and manage IV infiltration more effectively. In my own research, we’ve looked at how sensor technology can help reduce PIV complications in neonates. For instance, Matheus van Rens et al. demonstrated how early detection systems, when implemented in NICUs, can dramatically reduce the severity of complications. Our findings align with recent work by Vito D'Andrea et al. (2023), who introduced a novel optical device capable of detecting IV infiltration up to 6 hours earlier than traditional methods! ?? Key Insights: - 88.9% sensitivity and 84.4% specificity for detecting IV infiltration, leading to earlier interventions. - Combining human expertise with technological tools ensures better outcomes, as clinical judgment is essential alongside these devices. With such promising developments, I believe we’re on the cusp of a major shift in how we approach vascular access in neonates, reducing complications and improving outcomes. This is a testament to the power of collaboration between research and clinical practice. The future of neonatal care is here, and it's looking brighter every day! #NeonatalCare #IVInfiltration #ivWatch #VascularAccess #InnovationInHealthcare #PatientSafety #NeonatologyResearch

This should be well worth a watch

Myopia is on the rise. For age-appropriate* children, MiSight? 1 day can help. It’s the first and only? FDA-approved* soft contact lens to slow myopia progression in children aged 8-12 at the initiation of treatment.2§ Learn more about #myopiacontrol here: https://loom.ly/SwwERAU #myopia #MiSight #MyopiaAwareness #carusoeyecare #eyecare #eyehealth #floridaeyedoctor #targetoptical ?Only FDA-approved soft contact lens designed for myopia control in the U.S. §Compared to a single-vision 1-day lens over a 3-year period. 1Theophanous C, Modjtahedi BS, Batech M, Marlin DS, Luong TQ, Fong DS.Myopia prevalence and risk factors in children. Clin Ophthalmol. 2018;12:1581-1587. Published 2018 Aug 29. doi:10.2147/OPTH.S164641 2Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight? Lenses for Myopia Control. Optom Vis Sci.2019; 96(8)556-567

Delving into the intricacies of #newbornhealth, our latest research introduces a pioneering framework for distinguishing specific pathologies from the cries of infants, a critical yet challenging task in early healthcare. Leveraging insights from #music and #speech_processing, we've crafted an innovative approach, spotlighting the potential of neighborhood component analysis (NCA) for feature selection. Excitingly, our results showcase an impressively high accuracy with a very low-cost architecture attained through the decision template fusion (#DTF) technique and a remarkable feat of feature space reduction, from 86 elements to just 6, with #NCA. These findings hold promise for revolutionizing early pathology detection in newborns, offering a glimpse into a future where precision healthcare begins at birth. Join us in decoding the language of infant cries and reshaping the landscape of newborn care. #NewbornHealth #artificialintelligence #Audiosignalprocessing #SepsisDetection #ResearchBreakthroughs Read more in our recent publication with #JASA: https://lnkd.in/enUpbu2h

?? We are pleased to announce the release of a comprehensive White Paper titled ‘?????????????? ?????????????????? ?????? ???????????????? ???????????????? ??????????????????: ?????? ???????? ???? ??????’. The white paper provides a thorough analysis of the urgent need for NBS for DMD. It offers information and guidance for national patient organizations to advocate for starting a NBS program for DMD in their country or region. The paper was developed by a working group and reviewed by leading experts in the field. ?? Access the white paper by clicking the link below. https://lnkd.in/eV7S-A8M #Duchenne #NewbornScreening #Healthcare #EarlyDiagnosis

Over the past few decades, research has clearly shown that there are distinct characteristics of ischemic heart disease in women that are not seen in men. While women often need tailored diagnostic approaches for diagnosis and treatment, the one-size-fits-all approach using male heart disease presentations as the standard of care has likely impacted female mortality in terms of cardiac deaths, which is the No. 1 killer in the world for both men and women. Emily Lau, MD, director of the Cardiometabolic Health and Hormones Clinic at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, shed light on the critical issue of gender differences in chest pain imaging evaluations in sessions at the American College of Cardiology (ACC) 2024 meeting earlier this year. Click here to learn more: https://lnkd.in/eDtyu8Ag The Acarix CADScor System is a point-of-care diagnostic aid that can easily be incorporated early in the diagnostic pathway to assess coronary artery disease. The device uses highly sensitive acoustics and advanced computational processing to analyze a patient's coronary blood flow. The system rapidly calculates a patient-specific CAD-score, indicating the patient’s risk of coronary stenosis as low or elevated. Learn more: https://lnkd.in/e-M8PtE2 #Acarix #CADScor #CADScorSystem #CAD #coronaryarterydisease #womenshealth #ACC

How can we revolutionize emergency care in environments where traditional blood transfusions aren't possible? Our #HealLA 2024 cohort member, ReBlood Rx, is developing polymerized hemoglobin-based oxygen carriers (HBOCs) designed to improve remote damage control resuscitation (RDCR). This groundbreaking technology, led by founders Carlos J. Munoz, CEO, and Christopher Caballero, COO, targets environments where traditional crystalloids fall short due to their lack of oxygen-carrying capacity, offering a practical substitute for blood transfusions. ?? Carlos J. Munoz shares, "In the next 5-10 years, ReBlood Rx envisions a fully cleared FDA product for pre-hospital care situations where blood is needed but not available, increasing medical capabilities for people living in rural environments." This innovation has the potential to revolutionize field medicine, eliminating the need for refrigeration, crossmatching, and supply issues, ultimately enhancing the care provided by combat medics and pre-hospital care providers. We are proud to support ReBlood Rx, as they aim to transform emergency care and increase accessibility for all. ?? ____ HealLA provides a free, nine-month accelerator program aimed at nurturing and scaling innovations that address healthcare insecurity, inequities, and lack of preventive care. The HealLA Bioscience and Healthcare Accelerator is supported by esteemed partners such as the California Office of the Small Business Advocate (CalOSBA), U.S. Small Business Administration (SBA), Gilead Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, BioscienceLA, Cedars-Sinai, Keck School of Medicine of the University of Southern California, UCLA Technology Development Group, Biocom California, MedTech Color, Consortium for Technology & Innovation in Pediatrics (CTIP), California State University, Los Angeles, City of Hope, BioLabs, Rio Hondo College, Alliance for Southern California Innovation, Rancho Los Amigos National Rehabilitation Center, Keck Graduate Institute, WuXi Biologics. Learn more about the HealLA Bioscience and Healthcare Accelerator: https://lnkd.in/gi94ZB_f Discover the 2024 HealLA cohort: https://lnkd.in/gKRdHdzm #EmergencyCareInnovation #HBOCs #FieldMedicine #RemoteResuscitation #HealthcareInnovation #HealLA

March is #EndometriosisAwarenessMonth, so this #FemTechFriday, I'd like to share how FemTech is filling a critical gap in addressing endometriosis. Endometriosis, affecting 10% of females of reproductive age (over 190 million globally!), causes tissue similar to the uterine lining to grow outside the uterus. Despite its prevalence, it remains under-researched and under-diagnosed, with an average wait time of seven years to receive a diagnosis and laparoscopy as the only definitive method. Hera Biotech and The Feinstein Institutes' ROSE Study are changing that by developing nonsurgical diagnostic tools. These could completely revolutionize endometriosis care, saving patients time, money, and years of pain. The science behind these innovations is fascinating! I had the pleasure of interviewing both Somer Baburek, MBA of Hera and Professor Christine Metz of the ROSE Study for the FemTech Focus podcast (check the comments for links!). Want to know more? ?? Get educated with Endometriosis UK's Endometriosis Awareness Month resources. ?? Listen to the episodes linked in the comments to learn what the future of nonsurgical diagnostic tools holds. ?? Stay updated on FemTech advancements by following me here and subscribing to FemTech Focus. Let's keep raising awareness and destigmatizing endometriosis while supporting the incredible work in FemTech!

Are you having trouble sourcing a diverse range of mid-term and long-term plateable primary human hepatocytes (PHH) for your research? LifeNet Health has a portfolio of 147 donors, with 106 providing mid-term (5-10 days) and long-term (10-14 days) plateable PHH. Key highlights of LifeNet Health’s MT/LT plateable PHH offerings include: Health Status – 52 Healthy {NAS 0}, 10 Diseased {NAS 24} Quantity of Vials – 9 Lots with 900+ vials Race – 3 Asian, 13 Black, 16 Hispanic, 71 Caucasian Gender – 39 Female, 67 Male Life Stage – 96 Adult, 10 Pediatric/Juvenile LifeNet Health is committed to combining quantity, quality, and diversity to meet your research needs. Our extensive PHH portfolio offers a wide selection of high-quality cells, enhancing the relevance and translational potential of your studies. For more information on how we can help with your research needs, please visit the link below: https://lnkd.in/e6Bvmq8s #lifesciences #liverresearch